Key Highlights

  • Kenvue (NYSE:KVUE) traded at USD 17.76, down 0.39%, on October 14, 2026, with a market value of USD 34.11 billion, a Bollinger Band width of 4.53% and an average daily range of 1.73% of price.
  • The catalyst is the pending takeover: each Kenvue share converts into 0.14625 shares of Kimberly-Clark plus USD 3.50 in cash, in a deal with an enterprise value of about USD 48.7 billion.
  • Shareholders of both companies approved the deal on January 29, 2026, the U.S. antitrust waiting period expired on February 4, and closing is expected in the fourth quarter of 2026 pending foreign approvals.
  • Second-quarter net sales were USD 3.96 billion, up 3.0%, with organic growth of 1.6% and adjusted EPS of USD 0.31, and Kenvue gives no guidance because of the transaction.

The Deal Behind the Quiet Chart

The 0.39% decline on October 14, 2026 has no company announcement behind it. The material catalyst is the agreement signed on November 2, 2025 for Kimberly-Clark to acquire Kenvue (NYSE:KVUE). Each Kenvue share converts into 0.14625 Kimberly-Clark shares plus USD 3.50 in cash, so the value received moves with the acquirer's share price. Kimberly-Clark holders are expected to own about 54% of the combined company and Kenvue holders about 46%. A Bollinger Band width of 4.53% shows the stock trading in a tight range, which is typical when a stock tracks a fixed exchange ratio, and it carries no directional signal. Investors treat the offer as the main driver of the stock.

Why the Stock Tracks the Acquirer

In a stock-and-cash deal, the target's price is usually anchored to the offer value, which equals the cash plus the exchange ratio times the acquirer's price. Arbitrage investors may buy the target and short the acquirer to capture the gap, which narrows as closing nears. That relationship explains the low average true range of 1.73% of price. The business itself grew modestly: second-quarter net sales of USD 3.96 billion rose 3.0%, organic sales rose 1.6%, adjusted EPS rose to USD 0.31 from USD 0.29 and GAAP EPS was USD 0.24. Because of the pending transaction, Kenvue provides no outlook. Consumer health brands such as Tylenol and Neutrogena are sold worldwide, which is why many regulators review the combination.

Risks and What to Watch

Closing depends on foreign regulatory approvals and other customary conditions, so any delay would extend the wait and could widen the gap between the offer value and the share price. Falling Kimberly-Clark shares would reduce the value of the stock component. Integration and the combined company's leverage are longer-term risks. Investors should watch regulatory announcements, the closing date and any update in Kimberly-Clark disclosures. If the deal has not closed by then, Kenvue's quarterly results would normally follow in early November, based on its usual calendar. Nothing in the data suggests a break, but timing is uncertain. Kimberly-Clark (NASDAQ:KMB) shares set the stock portion of the offer, so its moves matter.

Where Things Stand

The answer is that Kenvue (NYSE:KVUE) is expected to close its Kimberly-Clark deal in the fourth quarter of 2026, pending foreign approvals, but no closing date has been given. Shareholder votes and the U.S. waiting period are complete. The 4.53% band width shows trading tied to the exchange ratio. Regulatory timing is the next catalyst. This is not investment advice. Foreign approvals and the fourth-quarter timetable are the main items to follow.